Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 569-575

  Goyal, Rakesh K ^a,b   Han, Kelong ^c   Wall, Donna A ^d   Pulsipher, Michael A ^e   Bunin, Nancy ^f   Grupp, Stephan A ^f   Mada, Sripal R ^c   Venkataramanan, Raman ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d TEXAS TRANSPLANT INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Fluconazole; Graft versus host disease; Population pharmacokinetic analysis; Therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B; CYCLOPHOSPHAMIDE; FLUCONAZOLE; METHOTREXATE; MICAFUNGIN; RAPAMYCIN; TACROLIMUS; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HUMAN; MALE; MASS SPECTROMETRY; MYCOSIS; MYELOABLATIVE CONDITIONING; NONLINEAR SYSTEM; PRESCHOOL CHILD; RECIPIENT; SCHOOL CHILD; STEADY STATE;

ADOLESCENT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; FLUCONAZOLE; GRAFT VS HOST DISEASE; HALF-LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYELOABLATIVE AGONISTS; SIROLIMUS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84875499025     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.015     Document Type: Article

References (25)

1. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001, 72:1924-1929.
2. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003, 102:1601-1605.
3. Anglicheau D., Le Corre D., Lechaton S., et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005, 5:595-603.
4. Glotzbecker B., Duncan C., Alyea E., et al. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant 2012, 18:989-1006.
5. Cervelli M.J. Fluconazole-sirolimus drug interaction. Transplantation 2002, 74:1477-1478.
6. Marty F.M., Lowry C.M., Cutler C.S., et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:552-559.
7. Zhang S., Pillai V.C., Mada S.R., et al. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 2012, 42:409-416.
8. Schachter A.D., Meyers K.E., Spaneas L.D., et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004, 8:171-177.
9. Schubert M., Venkataramanan R., Holt D.W., et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004, 4:767-773.
10. Pulsipher M.A., Wall D.A., Grimley M., et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft-versus-host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009, 147:691-699.
11. Holt D.W., Lee T., Jones K., et al. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000, 46(8 Pt 1):1179-1183.
12. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:551-557.
13. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
14. Zimmerman J.J., Kahan B.D. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997, 37:405-415.
15. Schachter A.D., Benfield M.R., Wyatt R.J., et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006, 10:914-919.
16. Tejani A., Alexander S., Ettenger R., et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 2004, 8:151-160.
17. Young C.J., Gaston R.S. Renal transplantation in black Americans. N Engl J Med 2000, 343:1545-1552.
18. Mancinelli L.M., Frassetto L., Floren L.C., et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001, 69:24-31.
19. Gaviria M., Gil A.A., Javaid J.I., et al. Nortriptyline kinetics in Hispanic and Anglo subjects. J Clin Psychopharmacol 1986, 6:227-231.
20. Langaee T.Y., Gong Y., Yarandi H.N., et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007, 81:386-391.
21. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
22. Jacobson P., Ng J., Ratanatharathorn V., et al. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 2001, 28:753-758.
23. Saad A.H., DePestel D.D., Carver P.L., et al. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006, 26:1730-1744.
24. Kubiak D.W., Koo S., Hammond S.P., et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1462-1465.
25. Sadaba B., Campanero M.A., Quetglas E.G., et al. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004, 36:3226-3228.